ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

ACI-19764

A development code. Also written as “ACI-19764 at dose A1”, “ACI-19764 at dose A2” and “ACI-19764 at dose A3”.

Its studies are mostly in Obesity, led by AC Immune.

Furthest: phase 1, since Feb 18, 20261 company-led study, 1 open or runningNext primary completion: Dec 2026 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AC Immune11 open or runningphase 1since Feb 18, 2026Feb 18, 2026Dec 2026phase 1 · NCT07463196

Also a collaborator on its studies: ICON Clinical Research.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Feb 18, 2026First study: phase 1 study in ObesityFirst studyNCT07463196 · 114 planned · Netherlands

Ahead

  1. Dec 2026Primary completion: phase 1 study in ObesityNCT07463196

TargetBeta

NLRP3 →read by rule
“ACI-19764 is a brain-penetrant NLRP3 inhibitor.”study text, by rule · the study

Other programs on NLRP3

ProgramCompanyFurthest phaseStudies
parunoflastEli Lillyphase 23
abdenoflastEli Lillyphase 22

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07463196Obesity · Netherlands1RecruitingDec 2026114

How it is read

Names in the registry

  • “ACI-19764 at dose A1”, 1 entry
  • “ACI-19764 at dose A2”, 1 entry
  • “ACI-19764 at dose A3”, 1 entry
  • “ACI-19764 at dose A4”, 1 entry
  • “ACI-19764 at dose A5”, 1 entry

Codes read as this program: ACI19764.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.